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Abstract

Literature Review

Discussion

• Clostridium difficile infection (CDI) is the main cause of
antibiotic-associated pseudomembranous colitis.

Pathophysiology
•Bakken, 2009; Normal gut flora comprised of strict anaerobes such
as: Peptostreptococcus, Prevotella, Ruminococcus, Bacteroides,
Bifidobacterium, Eubacterium, and Lactobacillus.

• van Nood et al. (2013) randomized clinical trial comparing
vancomycin and FMT effectiveness in the treatment of recurrent
CDI.

• CDI has tripled over the last ten years due to the increased
use of broad spectrum antibiotics. CDI has become
increasingly difficult to manage with traditional therapies
such as metronidazole and vancomycin due to mutations in
the pathogen, resulting in resistant organisms.
• The purpose of this review was to determine if fecal
microbiota transplantation (FMT) is more effective in treating
and curing CDIs than traditional vancomycin therapy.
• The hypothesis was that FMT will have better treatment
outcomes than traditional vancomycin therapy.
• The findings indicated that FMT is a more cost effective,
safer, and overall better treatment option for CDI than
traditional therapies such as vancomycin.

Introduction
• The purpose of this review is to determine if fecal microbiota
transplantation (FMT) is more effective in treating and curing
Clostridium difficile infections (CDIs) than traditional
vancomycin therapy.
• The literature will examine research comparing treatment
outcomes of FMT to vancomycin treatment in individuals with
resistant CDI.
• This information will enable one to compare treatment outcomes
between the two therapies, as well as the best delivery method for
FMT.

Statement of the Problem
• CDI has become increasingly difficult to manage with traditional
therapies such as metronidazole and vancomycin due to mutations
in the pathogen resulting in resistant organisms.
• These drug resistant pathogens have caused death, longer hospital
stays, and increased nosocomial infections due to the highly
infectious nature of the spore forming CDI pathogen.

Research Questions
1. In people with recurrent CDI, does FMT have better
treatment outcomes and less recurrence of CDI episodes
than traditional vancomycin therapy?
2. Do people who undergo FMT have better success rates
with nasogastric or colonic administration of FMT?

•Grehan et al., 2010; Individuals with C. difficile, aerobic and
facultative anaerobic bacteria dominate the gut flora.
•Borody et al., 2004; C. difficile not problematic until the beneficial
gastrointestinal microbiota is depleted

•Gough et al., 2011; CDIs recur in 35% of the patient population
after treatment with antibiotic therapy, and 65% of these patients
develop chronic re-manifestations of CDI.

• FMT has been partially accepted as a therapy for CDI only
because the medical field is running out of good options to treat
recurrent CDI. The rising number of cases of vancomycin
resistant enterococci (VRE) is forcing FMT to the front lines as a
primary treatment option in these cases.

•Agito et al., 2013; Subsequent CDI rates double after two or more
infections.

•Gough et al., 2011; FMT was found to be safe and effective. 27
case series with 317 patients were examined where vancomycin
treatment had failed. Disease resolution in 92% of cases after FMT.
•Kassam et al., 2012; performed a systematic review and metaanalysis which examined eleven studies with a total of 273 patients
with recurrent CDI treated with FMT that had failed prior treatment
with vancomycin. Researchers found CDI resolution in 89.7% of
patients involved in the study.
Nasogastric tube (NGT) or Colonic administration of FMT
Table 2, Postigo & Kim (2012): Outcomes of patients who underwent FMT via
either NGT or colonoscopy for recurrent CDI treatment

NGT group, Colonoscopy group, P-value
n=34
n=148
Resolution after FMT
(%)

29
(85.3)

138
(93.2)

No resolution after FMT
(%)

5
(14.7)

10
(6.8)

Relapse after FMT
(%)

2
(5.9)

8
(5.4)

No relapse after FMT
(%)

32
(94.1)

140
(94.6)

Death due to CDI after
FMT (%)

0
(0.0)

4
(2.7)

0.162

1.000

1.000

• After reviewing the outcomes of FMT in the literature and
examining CDI recurrence rates with currently suggested
treatment protocols, I believe we are not using the best first-line
treatment option for CDI cases. FMT should be used as a firstline treatment and not a last ditch effort. Outcomes for FMT are
better than vancomycin, as well as more durable.
• Although more research is needed in these areas, FMT was also
successfully utilized in the treatment of ulcerative colitis, IBS,
and crohns. Implications for FMT were directed at the treatment
of celiac and other colonic infections and disturbances. The
primary obstacle keeping FMT from branching out as a treatment
option in the afore mentioned areas is public acceptance of the
therapy.

•Bakken, 2009; C. difficile has a spore-coat protecting the organism,
it is relatively resistant to broad spectrum antibiotics, while the
majority of the gut’s other beneficial microbiota is not.

FMT versus Vancomycin in treating recurrent CDI
•Van Nood et al., 2013; First randomized clinical trial to pit FMT
against vancomycin in the treatment of recurrent CDI

Applicability to Clinical
Practice

• Gough et al., 2011; 27 case series and reports were examined with
a total of 317 patients. Patients had recurrent CDI not cured by
multiple treatments with vancomycin. 89% cure rate of CDI after
a single FMT treatment and 92% after a second treatment. Only
5% of patients had CDI relapse.
• Postigo and Kim, 2012; No statistical difference in the treatment
efficacy between NG tube and colonoscopy guided FMT. All
studies examined commented that FMT was a safe treatment
option with relatively few adverse side effects.
• Borody & Campbell, 2012; other possible clinical uses for FMT:
crohns , ulcerative colitis, IBS, non-genetic autism, celiac . . . .

• The medical field uses other bodily fluids on a daily basis for
their beneficial attributes. Fecal matter is no different. Let’s not
waste a valuable resource by flushing it away. Save it for FMT!
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